How Does Medical Device Reimbursement Work? The Coding, Coverage, Payment Primer

2026-09-25 · Caduvo Team

An end-to-end primer on US medical device reimbursement: how coding, coverage, and payment work, and why reimbursement strategy must start before design freeze. Includes a founder’s checklist.

You have FDA clearance. Your device is in a carton. But hospitals are asking a simple question: “What’s the code?” Without a payment pathway, a cleared device doesn’t sell. Reimbursement — coding, coverage, and payment — is a distinct regulatory system that can delay market entry by two years or kill a product entirely. If you wait until after design freeze to think about it, you’re already late.

The Three-Legged Stool: Coding, Coverage, Payment

Medical device reimbursement in the US stands on three parts. You need all three to get paid.

Coding A code describes what was done and what was used. Physician services use CPT codes; devices and supplies often use HCPCS Level II codes. If a code doesn’t exist, you can’t submit a claim. Many new devices fit existing codes — but not always. For instance, a novel ablation catheter may need a new CPT Category III code, a temporary code that tracks emerging technology but doesn’t guarantee payment. Manufacturers apply through the AMA CPT Editorial Panel or CMS. The process takes 12–24 months. The distinction between CPT and HCPCS matters; for a deeper look, see HCPCS vs CPT Codes: What MedTech Teams Need to Know.

Coverage A payer decides whether a service or item is “reasonable and necessary.” Medicare coverage comes through National Coverage Determinations (NCDs, binding nationwide) or Local Coverage Determinations (LCDs, set by Medicare Administrative Contractors in each region). Most medical devices are covered via LCDs, not NCDs. If no LCD exists, MACs decide case-by-case. Commercial payers have their own policies, often influenced by Medicare but not bound by it. A Medicare LCD won’t automatically trigger commercial coverage. For a detailed breakdown, read NCDs vs LCDs: How Medicare Coverage Determinations Work for Device Companies.

Payment Once coded and covered, payment sets the actual dollar amount. For physician office procedures, that’s the Medicare Physician Fee Schedule; for hospital outpatient, the Outpatient Prospective Payment System (OPPS) and APCs; for inpatient, MS-DRGs; for DME, the Medicare DME Fee Schedule. The payment rate depends on the code’s assigned APC or DRG weight. A new code that pushes a procedure into a higher-weighted DRG can make a device economically viable — or not.

Medicare vs. Commercial Payers: Two Different Games

Medicare is the largest payer and sets a benchmark, but commercial payers move independently. A Medicare LCD provides some air cover, but UnitedHealthcare, Aetna, and others issue their own medical policies. Typically, commercial policies lag 12–18 months behind Medicare, if they align at all. For example, a device used in total knee arthroplasty may be covered by Medicare through an existing DRG, but a commercial plan may demand evidence of lower revision rates at two years before adding it to their policy. That means multi-year evidence generation.

Early-stage companies should prioritize Medicare because it creates a coverage beachhead. Then build evidence packages that meet the specific requirements of targeted commercial plans. Don’t assume a Medicare win will open all doors.

Why Reimbursement Strategy Starts Before Design Freeze

The single most expensive mistake is designing a device, locking the feature set, and then asking the reimbursement question. Reimbursement influences device design.

First, coding. A feature you add for differentiation might inadvertently push the product out of an existing code or require a new code application. A simple example: adding a sensor or AI component to a surgical tool could bump it from a well-reimbursed, established CPT code into an unlisted category, or trigger a need for a HCPCS code with no assigned payment. The FDA pathway also interacts here. A Breakthrough Device Designation can open a door to Medicare’s Transitional Coverage for Emerging Technologies (TCET) program, but only if you plan for it early. See Breakthrough Device Designation: FDA Fast-Track and Medicare Payment Realities for the specifics.

Second, evidence. Payers demand clinical evidence that shows improved outcomes or cost savings for a specific patient population. If your trial endpoints were chosen only for FDA clearance, they may be useless for coverage. Your clinical study design should incorporate endpoints that matter to payers — things like reduced length of stay, lower readmission rates, or functional improvement — from the start. Starting evidence generation after FDA clearance can add years to reimbursement.

Third, timing. A new CPT code application cycle starts months before the AMA meeting. If you file late, you miss the window and wait another year. MACs can take 9–12 months to finalize an LCD. That means without early planning, you could have a cleared device and no coverage pathway for 2–3 years post-FDA.

A Founder’s Reimbursement Readiness Checklist

Act on these items before design freeze or immediately after your first prototype.

1. Map existing codes. Search the CPT and HCPCS code sets for codes that could describe your procedure or device. If none exist, plan a new code application timeline.
2. Search the Medicare Coverage Database. Identify any NCDs or LCDs that might apply or restrict coverage for similar technology.
3. Engage a MAC medical director early. A pre-submission meeting can reveal what evidence a MAC expects for a future LCD request.
4. Build a payer-relevant evidence plan. Define endpoints beyond safety and efficacy: cost-effectiveness, resource utilization, patient-reported outcomes. Run the plan past a payer advisory panel.
5. Integrate coding features into device design. For example, if your device could be used percutaneously or open, decide which approach aligns with a higher-payment code — and design accordingly.
6. Sequence commercial payers. After a Medicare LCD, identify 3–5 commercial plans with largest covered lives in your target geography and request their policy development process.
7. Align FDA and reimbursement timelines. If you’re pursuing Breakthrough Device Designation, explore TCET eligibility and what it demands in terms of evidence.

The payoff for early work is simple: a device that launches with a code, a coverage policy, and a known payment rate, rather than one that lands in a warehouse while you scramble to fill out a CPT application.